DSS
MCID: DNG001
MIFTS: 47

Dengue Shock Syndrome (DSS)

Categories: Infectious diseases

Aliases & Classifications for Dengue Shock Syndrome

MalaCards integrated aliases for Dengue Shock Syndrome:

Name: Dengue Shock Syndrome 12 55 15 73
Dss 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050125
UMLS 73 C0376300

Summaries for Dengue Shock Syndrome

Disease Ontology : 12 A dengue disease that involves the most severe form of dengue fever, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted by Aedes mosquito bite. The infection has symptom easy bruising, has symptom blood spots, has symptom bleeding gums, and has symptom nosebleeds. It is accompanied by circulatory collapse, involves hypotension, narrow pulse pressure (less than or equal to 20mm Hg), or frank shock. The shock occurs after two to six days of symptoms, followed by collapse, weak pulse, and blueness around the mouth.

MalaCards based summary : Dengue Shock Syndrome, also known as dss, is related to colitis and ulcerative colitis, and has symptoms including easy bruising, bleeding gums and blood spots. An important gene associated with Dengue Shock Syndrome is THBD (Thrombomodulin), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Human cytomegalovirus infection. The drugs Ketotifen and Histamine have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and liver.

Related Diseases for Dengue Shock Syndrome

Diseases related to Dengue Shock Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 colitis 31.8 IL1B IL6 TNF
2 ulcerative colitis 31.1 IL1B IL6 TNF
3 hemorrhagic fever 30.8 HLA-DRB1 IL6 TNF
4 dengue hemorrhagic fever 30.3 CMA1 HLA-A HLA-DRB1 IL6 TNF
5 viral infectious disease 30.1 IL1B IL6 TNF
6 perinatal necrotizing enterocolitis 29.9 IL1B IL6 TNF
7 acute respiratory distress syndrome 29.8 IL1B IL6 TNF
8 purpura 29.7 IL6 THBD TNF
9 inflammatory bowel disease 29.5 CCL2 HLA-DRB1 IL1B IL1RN IL6 TNF
10 multiple sclerosis 29.4 CCL2 HLA-DRB1 IL1B IL6 TNF
11 diabetes mellitus 29.1 HLA-A HLA-DRB1 IL1B IL1RN IL6 TNF
12 malaria 28.3 CCL2 HLA-A HLA-DRB1 IL1B IL1RN IL6
13 dengue disease 12.3
14 dengue virus 11.6
15 hypertrophic neuropathy of dejerine-sottas 11.4
16 46,xy sex reversal 2 11.4
17 neuropathy, congenital hypomyelinating or amyelinating, autosomal recessive 11.3
18 charcot-marie-tooth disease, demyelinating, type 4f 11.1
19 colorectal cancer 10.3
20 gastric cancer, hereditary diffuse 10.3 IL1B IL1RN
21 schnitzler syndrome 10.3 IL1B IL1RN
22 retinitis pigmentosa 60 10.2 IL1B TNF
23 kashin-beck disease 10.2 IL1B TNF
24 burns 10.2 IL1B TNF
25 crohn's colitis 10.2 IL1B TNF
26 opisthorchiasis 10.2 IL1B TNF
27 irritant dermatitis 10.2 IL1B TNF
28 rheumatoid lung disease 10.2 IL1B TNF
29 haemophilus influenzae 10.2 IL1B TNF
30 scleral disease 10.2 IL1RN TNF
31 pustulosis of palm and sole 10.2 IL1RN TNF
32 funisitis 10.2 IL1B IL6
33 euthyroid sick syndrome 10.2 IL1B IL6
34 uremic pruritus 10.2 IL1B IL6
35 acute cholangitis 10.2 IL1RN IL6
36 retinitis pigmentosa 55 10.2 IL6 TNF
37 autoimmune gastritis 10.2 IL6 TNF
38 meconium aspiration syndrome 10.2 IL6 TNF
39 burning mouth syndrome 10.2 IL6 TNF
40 exudative glomerulonephritis 10.2 IL1B TNF
41 null-cell leukemia 10.2 IL6 TNF
42 posterior urethral valves 10.2 IL6 TNF
43 cardiogenic shock 10.2 IL6 TNF
44 microscopic colitis 10.2 HLA-DRB1 TNF
45 sympathetic ophthalmia 10.2 HLA-DRB1 TNF
46 rheumatoid vasculitis 10.2 HLA-DRB1 TNF
47 chronic beryllium disease 10.2 HLA-DRB1 TNF
48 rheumatoid arthritis, systemic juvenile 10.1 HLA-DRB1 IL6
49 systemic onset juvenile idiopathic arthritis 10.1 IL1RN TNF
50 recurrent corneal erosion 10.1 IL1B IL6

Graphical network of the top 20 diseases related to Dengue Shock Syndrome:



Diseases related to Dengue Shock Syndrome

Symptoms & Phenotypes for Dengue Shock Syndrome

Symptoms:

12
  • easy bruising
  • bleeding gums
  • blood spots
  • nosebleeds

Drugs & Therapeutics for Dengue Shock Syndrome

Drugs for Dengue Shock Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
2
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
3 Anti-Allergic Agents Phase 4
4
Histamine Phosphate Phase 4 51-74-1 65513
5 Antipruritics Phase 4
6 Histamine H1 Antagonists Phase 4
7 Neurotransmitter Agents Phase 4
8 Dermatologic Agents Phase 4
9 Histamine Antagonists Phase 4
10
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 6474909
11 Pharmaceutical Solutions Phase 3,Phase 2
12 Anti-Infective Agents Phase 2, Phase 3
13 Antiparasitic Agents Phase 2, Phase 3
14 Immunologic Factors Phase 3,Phase 2,Phase 1
15 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
17
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
18
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
19
Ribavirin Approved Phase 2 36791-04-5 37542
20
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
21 Antimetabolites Phase 2
22 Hydrocortisone 17-butyrate 21-propionate Phase 2
23 Cortisol succinate Phase 2
24 Antiviral Agents Phase 2
25 Antibodies Phase 1, Phase 2,Phase 2
26 Immunoglobulins Phase 1, Phase 2,Phase 2
27
Aluminum sulfate Approved Phase 1 10043-01-3
28
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
29 Anti-Ulcer Agents Phase 1
30 Adjuvants, Immunologic Phase 1
31 Antacids Phase 1
32 Gastrointestinal Agents Phase 1
33
Permethrin Approved, Investigational Not Applicable 52645-53-1 40326
34 gamma-Globulins Not Applicable
35 Immunoglobulins, Intravenous Not Applicable
36 Rho(D) Immune Globulin Not Applicable

Interventional clinical trials:

(show top 50) (show all 109)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
4 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Unknown status NCT01374516 Phase 3
5 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
6 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
7 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
8 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue Completed NCT03423173 Phase 3
9 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
10 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
11 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
12 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
13 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
14 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
15 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults Not yet recruiting NCT03771963 Phase 3
16 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
17 Celgosivir as a Treatment Against Dengue Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
18 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
19 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
20 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
21 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore Completed NCT02425098 Phase 2
22 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
23 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
24 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
25 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Completed NCT00468858 Phase 2
26 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
27 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
28 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
29 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
30 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
31 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
32 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
33 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
34 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
35 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
36 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
37 Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults Recruiting NCT03746015 Phase 2
38 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Recruiting NCT03432442 Phase 2 Ivermectin
39 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Active, not recruiting NCT02824198 Phase 2
40 Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Active, not recruiting NCT02628444 Phase 2
41 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule Active, not recruiting NCT02623725 Phase 2
42 Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants Active, not recruiting NCT02302066 Phase 2 TDV Placebo
43 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Active, not recruiting NCT03110770 Phase 2
44 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
45 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Not yet recruiting NCT02741128 Phase 2
46 A Study of Balapiravir in Patients With Dengue Virus Infection Completed NCT01096576 Phase 1 balapiravir [RO4588161];placebo
47 Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever Completed NCT01224639 Phase 1
48 Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Completed NCT00458120 Phase 1
49 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults Completed NCT00831012 Phase 1
50 Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease Completed NCT01502735 Phase 1

Search NIH Clinical Center for Dengue Shock Syndrome

Genetic Tests for Dengue Shock Syndrome

Anatomical Context for Dengue Shock Syndrome

MalaCards organs/tissues related to Dengue Shock Syndrome:

41
Colon, T Cells, Liver, Bone, Heart, Lung, Monocytes

Publications for Dengue Shock Syndrome

Articles related to Dengue Shock Syndrome:

(show top 50) (show all 654)
# Title Authors Year
1
Effect of compound sophorae decoction on dextran sodium sulfate (DSS)-induced colitis in mice by regulating Th17/Treg cell balance. ( 30551499 )
2019
2
Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer. ( 30551398 )
2019
3
Joint ancestry and association test indicate two distinct pathogenic pathways involved in classical dengue fever and dengue shock syndrome. ( 29447178 )
2018
4
Dengue shock syndrome complicated with acute liver failure and kidney injury, infective endocarditis, and deep vein thrombosis: a case report. ( 30373645 )
2018
5
Palmatine attenuated dextran sulfate sodium (DSS)-induced colitis via promoting mitophagy-mediated NLRP3 inflammasome inactivation. ( 30496979 )
2018
6
Corrigendum to "3-(1H-Benzo[d]imidazol-6-yl)-5-(4-fluorophenyl)-1, 2, 4-oxadiazole (DDO7232), a Novel Potent Nrf2/ARE Inducer, Ameliorates DSS-Induced Murine Colitis and Protects NCM460 Cells against Oxidative Stress via ERK1/2 Phosphorylation". ( 30510629 )
2018
7
5-Hydroxytryptamine (5-HT)-exacerbated DSS-induced colitis is associated with elevated NADPH oxidase expression in the colon. ( 30525222 )
2018
8
PGlyRP3 concerts with PPARγ to attenuate DSS-induced colitis in mice. ( 30530168 )
2018
9
IL-33 Protects Mice against DSS-Induced Chronic Colitis by Increasing Both Regulatory B Cell and Regulatory T Cell Responses as Well as Decreasing Th17 Cell Response. ( 30539029 )
2018
10
Inhibition of ASM activity ameliorates DSS-induced colitis in mice. ( 30550872 )
2018
11
Constitutive androstane receptor and pregnane X receptor cooperatively ameliorate DSS-induced colitis. ( 30442521 )
2018
12
Prostaglandin E2 secreted from feline adipose tissue-derived mesenchymal stem cells alleviate DSS-induced colitis by increasing regulatory T cells in mice. ( 30453939 )
2018
13
The anti-inflammatory activity of peptides from simulated gastrointestinal digestion of preserved egg white in DSS-induced mouse colitis. ( 30462121 )
2018
14
Protective Effect of Naringin on DSS-Induced Ulcerative Colitis in Mice. ( 30472831 )
2018
15
Maternal High Fat Diet Alters Gut Microbiota of Offspring and Exacerbates DSS-Induced Colitis in Adulthood. ( 30483266 )
2018
16
Inhibition of NADPH oxidase activities ameliorates DSS-induced colitis. ( 30321511 )
2018
17
iNKT Cells Suppress Pathogenic NK1.1+CD8+ T Cells in DSS-Induced Colitis. ( 30333822 )
2018
18
ABIN2 Function Is Required To Suppress DSS-Induced Colitis by a Tpl2-Independent Mechanism. ( 30355787 )
2018
19
Curcumin alleviates DSS-induced colitis via inhibiting NLRP3 inflammsome activation and IL-1β production. ( 30396035 )
2018
20
Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice: Impact on microRNAs expression and gut microbiota composition. ( 30236870 )
2018
21
Semi-rational screening of the probiotics from the fecal flora of healthy adults against DSS-induced colitis mice by enhancing anti-inflammatory activity and modulating the gut microbiota. ( 30270604 )
2018
22
Sophora flavescens Containing-QYJD Formula Activates Nrf2 Anti-Oxidant Response, Blocks Cellular Transformation and Protects Against DSS-Induced Colitis in Mouse Model. ( 30284461 )
2018
23
Transcriptomic analysis reveals a controlling mechanism for NLRP3 and IL-17A in dextran sulfate sodium (DSS)-induced colitis. ( 30297787 )
2018
24
Environmental Factors Modify the Severity of Acute DSS Colitis in Caspase-11-Deficient Mice. ( 30312415 )
2018
25
Comparisons of gut microbiota profiles in wild-type and gelatinase B/matrix metalloproteinase-9-deficient mice in acute DSS-induced colitis. ( 30181895 )
2018
26
American ginseng microbial metabolites attenuate DSS-induced colitis and abdominal pain. ( 30212750 )
2018
27
Lactobacillus reuteri F-9-35 Prevents DSS-Induced Colitis by Inhibiting Proinflammatory Gene Expression and Restoring the Gut Microbiota in Mice. ( 30216448 )
2018
28
Cortical Inflammation is Increased in a DSS-Induced Colitis Mouse Model. ( 30225764 )
2018
29
SXP-RAL Family Filarial Protein, rWbL2, Prevents Development of DSS-Induced Acute Ulcerative Colitis. ( 30072827 )
2018
30
Rhamnogalacturonan, a chemically-defined polysaccharide, improves intestinal barrier function in DSS-induced colitis in mice and human Caco-2 cells. ( 30115942 )
2018
31
Molecular mechanisms of somatostatin-mediated intestinal epithelial barrier function restoration by upregulating claudin-4 in mice with DSS-induced colitis. ( 30020824 )
2018
32
Assessing Mucosal Inflammation in a DSS-Induced Colitis Mouse Model by MR Colonography. ( 30042983 )
2018
33
Extracellular Vesicles From the Helminth Fasciola hepatica Prevent DSS-Induced Acute Ulcerative Colitis in a T-Lymphocyte Independent Mode. ( 29875750 )
2018
34
Casticin prevents DSS induced ulcerative colitis in mice through inhibitions of NF-κB pathway and ROS signaling. ( 29876982 )
2018
35
3-(1H-Benzo[d]imidazol-6-yl)-5-(4-fluorophenyl)-1,2,4-oxadiazole (DDO7232), a Novel Potent Nrf2/ARE Inducer, Ameliorates DSS-Induced Murine Colitis and Protects NCM460 Cells against Oxidative Stress via ERK1/2 Phosphorylation. ( 29887940 )
2018
36
Propolis from Different Geographic Origins Decreases Intestinal Inflammation and Bacteroides spp. Populations in a Model of DSS-Induced Colitis. ( 29889351 )
2018
37
Dro1/Ccdc80 inactivation promotes AOM/DSS-induced colorectal carcinogenesis and aggravates colitis by DSS in mice. ( 29901779 )
2018
38
Nicotine treatment ameliorates DSS-induced colitis by suppressing MAdCAM-1 expression and leukocyte recruitment. ( 29901817 )
2018
39
Estrogen Receptor α Loss-of-Function Protects Female Mice From DSS-Induced Experimental Colitis. ( 29930983 )
2018
40
Amelioration of Experimental autoimmune encephalomyelitis and DSS induced colitis by NTG-A-009 through the inhibition of Th1 and Th17 cells differentiation. ( 29773813 )
2018
41
Alcohol enhances symptoms and propensity for infection in inflammatory bowel disease patients and a murine model of DSS-induced colitis. ( 29775230 )
2018
42
Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages. ( 29849131 )
2018
43
Deoxycholic Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Exacerbates DSS-Induced Colitis through Promoting Cathepsin B Release. ( 29854830 )
2018
44
The Administration of Escherichia coli Nissle 1917 Ameliorates Development of DSS-Induced Colitis in Mice. ( 29867475 )
2018
45
Serum fatty acids and progression from dengue fever to dengue haemorrhagic fever/dengue shock syndrome. ( 30105961 )
2018
46
Diabetic patients suffering dengue are at risk for development of dengue shock syndrome/severe dengue: Emphasizing the impacts of co-existing comorbidity(ies) and glycemic control on dengue severity. ( 30146413 )
2018
47
Alisma canaliculatum ethanol extract suppresses inflammatory responses in LPS-stimulated macrophages, HCl/EtOH-induced gastritis, and DSS-triggered colitis by targeting Src/Syk and TAK1 activities. ( 29574093 )
2018
48
Apple peel polyphenols reduce mitochondrial dysfunction in mice with DSS-induced ulcerative colitis. ( 29674247 )
2018
49
Root Extract of Polygonum cuspidatum Siebold & Zucc. Ameliorates DSS-Induced Ulcerative Colitis by Affecting NF-kappaB Signaling Pathway in a Mouse Model via Synergistic Effects of Polydatin, Resveratrol, and Emodin. ( 29695964 )
2018
50
Dihydrotanshinone I, a natural product, ameliorates DSS-induced experimental ulcerative colitis in mice. ( 29496522 )
2018

Variations for Dengue Shock Syndrome

Expression for Dengue Shock Syndrome

Search GEO for disease gene expression data for Dengue Shock Syndrome.

Pathways for Dengue Shock Syndrome

Pathways related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 CCL2 HLA-A HLA-DRB1 IL1B IL1RN IL6
2
Show member pathways
12.97 CCL2 HLA-A IL1B IL6 MICB TNF
3
Show member pathways
12.81 HLA-A HLA-DRB1 IL1B IL6 TNF
4
Show member pathways
12.66 CCL2 HLA-A HLA-DRB1 IL1B IL6 TNF
5
Show member pathways
12.53 HLA-DRB1 IL1B IL6 TNF
6
Show member pathways
12.52 CCL2 IL1B IL6 TNF
7 12.5 CCL2 IL1B IL1RN TNF
8 12.37 HLA-A HLA-DRB1 IL6 TNF
9
Show member pathways
12.29 CCL2 IL1B IL6 TNF
10
Show member pathways
12.28 CCL2 IL1B IL6 TNF
11 12.25 HLA-A HLA-DRB1 IL6 TNF
12
Show member pathways
12.2 HLA-A IL1B IL6 TNF
13 12.19 HLA-DRB1 IL1B IL6 TNF
14
Show member pathways
12.17 IL1B IL1RN IL6 TNF
15 12.13 IL1B IL1RN IL6 TNF
16
Show member pathways
12.1 IL1B IL6 TNF
17 12.02 CCL2 IL1B THBD TNF
18
Show member pathways
11.99 IL1B IL6 TNF
19
Show member pathways
11.97 IL1B IL6 TNF
20 11.93 CCL2 IL1B IL6 TNF
21
Show member pathways
11.92 HLA-A HLA-DRB1 IL1B
22 11.89 CCL2 IL1B IL6 TNF
23 11.87 CCL2 IL1B IL6 TNF
24
Show member pathways
11.85 CMA1 TNF TPSAB1
25 11.83 IL1B IL6 TNF
26 11.8 HLA-DRB1 IL1B IL6 TNF
27 11.73 IL1B IL6 TNF
28 11.67 CCL2 HLA-DRB1 IL1B IL6 TNF
29
Show member pathways
11.63 IL1B IL6 TNF
30 11.63 IL1B IL6 THBD TNF
31 11.56 IL1B IL6 TNF
32 11.51 CCL2 IL1B IL1RN IL6 TNF
33 11.49 CCL2 IL1B TNF
34 11.46 IL1B IL6 TNF
35 11.4 CCL2 IL1B IL6 TNF
36 11.35 CCL2 CMA1 IL1B IL6 TNF
37 11.32 IL1B IL6 TNF
38 11.31 IL1B IL6 TNF
39 11.29 CCL2 IL6 THBD
40 11.25 IL1B IL6 TNF
41 11.23 IL1B IL6 TNF
42 11.13 HLA-DRB1 IL1B IL6 TNF
43 11.11 CCL2 IL1B
44 11.1 CCL2 IL1B IL6 PLCE1 THBD TNF
45 11.06 CCL2 IL1B IL6 PLCE1 TNF
46 11.05 IL1B TNF
47 11.05 IL6 TNF
48 11.04 CCL2 IL1B IL1RN IL6 TNF
49 10.98 IL6 TNF
50 10.96 CCL2 IL1B IL6 PLCE1 TNF

GO Terms for Dengue Shock Syndrome

Cellular components related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CCL2 CMA1 IL1B IL1RN IL6 TNF
2 cell surface GO:0009986 9.35 HLA-A HLA-DRB1 MICB THBD TNF
3 extracellular space GO:0005615 9.23 CCL2 CMA1 IL1B IL1RN IL6 THBD

Biological processes related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.96 CCL2 IL1B IL1RN IL6 TNF
2 inflammatory response GO:0006954 9.89 CCL2 IL1B IL1RN IL6 TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.84 IL1B IL6 TNF
4 cytokine-mediated signaling pathway GO:0019221 9.83 CCL2 IL1B IL1RN IL6 TNF
5 activation of MAPK activity GO:0000187 9.82 IL1B PLCE1 TNF
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.81 IL1B IL6 TNF
7 neutrophil chemotaxis GO:0030593 9.8 CCL2 IL1B IL1RN
8 positive regulation of JNK cascade GO:0046330 9.8 IL1B IL1RN TNF
9 cellular response to organic cyclic compound GO:0071407 9.78 CCL2 IL1B TNF
10 humoral immune response GO:0006959 9.76 CCL2 IL6 TNF
11 positive regulation of JUN kinase activity GO:0043507 9.71 IL1B IL1RN TNF
12 protein kinase B signaling GO:0043491 9.69 CCL2 IL1B TNF
13 response to glucocorticoid GO:0051384 9.67 IL1B IL1RN IL6 TNF
14 positive regulation of chemokine production GO:0032722 9.66 IL6 TNF
15 negative regulation of lipid catabolic process GO:0050995 9.65 IL1B TNF
16 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.65 IL1B TNF
17 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 IL1B TNF
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.65 CCL2 IL1B TNF
19 cellular response to lipopolysaccharide GO:0071222 9.65 CCL2 IL1B IL1RN IL6 TNF
20 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.64 IL1B TNF
21 negative regulation of neurogenesis GO:0050768 9.63 IL1B IL6 TNF
22 negative regulation of lipid storage GO:0010888 9.62 IL6 TNF
23 positive regulation of interleukin-6 production GO:0032755 9.62 IL1B IL1RN IL6 TNF
24 positive regulation of chemokine biosynthetic process GO:0045080 9.61 IL1B TNF
25 negative regulation of glutamate secretion GO:0014050 9.6 IL1B IL1RN
26 regulation of establishment of endothelial barrier GO:1903140 9.59 IL1B TNF
27 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.58 IL1RN IL6
28 positive regulation of glial cell proliferation GO:0060252 9.58 IL1B IL6 TNF
29 positive regulation of fever generation GO:0031622 9.57 IL1B TNF
30 sequestering of triglyceride GO:0030730 9.55 IL1B TNF
31 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 IL1B TNF
32 positive regulation of neuroinflammatory response GO:0150078 9.33 IL1B IL6 TNF
33 immune response GO:0006955 9.23 CCL2 HLA-A HLA-DRB1 IL1B IL1RN IL6
34 chronic inflammatory response to antigenic stimulus GO:0002439 9.13 IL1B IL1RN TNF

Molecular functions related to Dengue Shock Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.02 CCL2 IL1B IL1RN IL6 TNF
2 interleukin-1 receptor binding GO:0005149 8.96 IL1B IL1RN

Sources for Dengue Shock Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....